Close

LANXESS: Price adjustment for PA 6.6 compounds

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

BioNTech and Gilead Partner for Pumitamig Clinical Trial

BioNTech SE has officially entered into a clinical trial...

Cencora to Acquire American Oncology Network in $2.4 Billion Deal

Cencora has signed a definitive agreement to acquire American...

Merck Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA has entered into an agreement to acquire...
- Advertisement -

LANXESS is raising its prices for Durethan A (polyamide 6.6) compounds in Europe, Middle East and Africa by EUR 0.60/kg with immediate effect.

The overall tight market situation with extremely limited availability of raw materials in the PA 6.6 value chain has led to further severe price increases for PA 6.6 base resin.

As there are no signs of a relief, a price adjustment is unavoidable.

The High Performance Materials business unit offers support in exploring opportunities to replace PA 6.6 applications by PA 6 or PBT grades.

About LANXESS
LANXESS is a leading specialty chemicals company with sales of EUR 9.7 billion in 2017 and about 19,200 employees in 25 countries. The company is currently represented at 74 production sites worldwide. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. Through ARLANXEO, the joint venture with Saudi Aramco, LANXESS is also a leading supplier of synthetic rubber. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.

 

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

BioNTech and Gilead Partner for Pumitamig Clinical Trial

BioNTech SE has officially entered into a clinical trial...

Cencora to Acquire American Oncology Network in $2.4 Billion Deal

Cencora has signed a definitive agreement to acquire American...

Merck Acquires Silence Therapeutics for $1.3 Billion

Merck KGaA has entered into an agreement to acquire...

5 Functional Medicine Clinics in Denver for a Personalized Approach to Chronic Inflammation

Chronic inflammation underlies a surprisingly wide range of diagnoses:...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »